What are the indications, dosing schedule, contraindications, and monitoring recommendations for tacrolimus ophthalmic drops?

Tacrolimus Ophthalmic: Clinical Guide

Primary Recommendation

Tacrolimus ophthalmic is used off-label as a topical calcineurin inhibitor for severe allergic eye diseases (vernal and atopic keratoconjunctivitis) that have failed conventional therapy, including topical corticosteroids, cyclosporine, and antiallergy medications. 1

---

Indications

FDA-Approved Indication

Tacrolimus is only FDA-approved as a dermatologic ointment (Protopic 0.03% and 0.1%) for atopic dermatitis, not for ophthalmic use 2. All ophthalmic applications represent off-label use 1.

Evidence-Based Ophthalmic Uses (Off-Label)

Primary indications:

• Vernal keratoconjunctivitis (VKC) - particularly severe cases refractory to other treatments 1
• Atopic keratoconjunctivitis - moderate to severe disease with eyelid and conjunctival involvement 1
• Refractory allergic conjunctivitis with proliferative lesions or corneal involvement 3

Secondary indications with emerging evidence:

• Severe corneal endothelial rejection refractory to corticosteroids 4
• Stromal herpetic keratitis (as adjunct therapy) 5
• Various anterior segment inflammatory conditions 6

---

Dosing Schedule

Age-Based Concentration Selection

Children (2-15 years):

• Use 0.03% concentration only 1, 7
• Apply twice daily to affected areas

Adults and adolescents (≥16 years):

• Use either 0.03% or 0.1% concentration 1, 7
• 0.1% concentration is preferred for severe disease based on randomized trials showing superior efficacy in adults with severe disease, extensive involvement, or in Black patients 1
• Apply twice daily

Application Sites

For eyelid involvement:

• Apply tacrolimus ointment (0.03% or 0.1% depending on age) to affected eyelid skin 1

For conjunctival/corneal involvement:

• Compounded tacrolimus eye drops (typically 0.1%) applied conjunctivally
• Dosing: Twice daily for maintenance 3
• For severe VKC: Twice daily has shown efficacy over 18 months 8
• For acute rejection: Four times daily until improvement, then taper 4

---

Contraindications

Absolute Contraindications

• Hypersensitivity to tacrolimus or any component 2

Relative Contraindications and Cautions

• Active herpes simplex keratitis - tacrolimus may increase susceptibility to HSV reactivation 1, 7
• Age <2 years - not studied and not recommended 1, 2
• Immunocompromised patients - use with extreme caution given theoretical malignancy risk 2

Important Safety Warnings

• Rare association with skin cancer and lymphoma has been reported with dermatologic use 1, 7
• This risk appears minimal with ophthalmic use due to limited systemic absorption 6

---

Monitoring Recommendations

Baseline Assessment

• Visual acuity measurement
• Slit-lamp biomicroscopy - document severity of papillae, hyperemia, corneal involvement
• Intraocular pressure (IOP) - establish baseline
• Pupillary dilation and lens examination - if patient has been on corticosteroids 1, 7

Follow-Up Schedule

Frequency depends on disease severity:

• Initial follow-up at 1-2 weeks to assess response and tolerance
• Then monthly visits during active treatment phase
• Less frequent monitoring once stable

At each visit, assess:

• Visual acuity - should improve with treatment 8, 3
• Interval history - symptoms, medication adherence, adverse effects
• Slit-lamp examination - grade hyperemia, papillae (tarsal, giant, limbal), corneal lesions 1, 8
• IOP measurement - particularly if concurrent corticosteroid use 1
• Lens examination - if on corticosteroids, check for cataract development 1

Laboratory Monitoring

Not routinely required for ophthalmic use - systemic absorption is minimal with topical ophthalmic application 6. Blood levels of tacrolimus and kidney/liver function tests are unnecessary unless using systemic tacrolimus concurrently.

---

Clinical Pearls and Pitfalls

Steroid-Sparing Benefits

Tacrolimus allows reduction or elimination of topical corticosteroids in approximately 50% of patients, avoiding steroid-related complications (glaucoma, cataracts) 1, 3. This is a major advantage for chronic management.

Response Timeline

• Expect improvement within 1-2 weeks for allergic conditions 3
• Full response may take 3-4 weeks 8
• For severe VKC refractory to cyclosporine, tacrolimus 0.1% shows sustained efficacy over 18 months 8

Common Adverse Effects

• Transient burning/stinging on instillation - most common complaint (3-4% of patients), typically diminishes over time 6, 3
• Punctate epithelial keratopathy - usually mild and self-limited 4

When to Consider Tacrolimus

Use tacrolimus when:

1. Conventional antiallergy medications have failed
2. Topical corticosteroids are needed chronically (steroid-sparing indication)
3. Topical cyclosporine has been inadequate 8, 3
4. Proliferative lesions or corneal involvement present 3

Vernal Keratoconjunctivitis Must Be Controlled

Before corneal cross-linking procedures, ensure VKC/atopic keratoconjunctivitis is well-controlled to decrease risk of sterile keratitis 1, 7.

Dermatology Consultation

Consider dermatology referral for patients with significant periocular atopic dermatitis requiring comprehensive management 1, 7.

---

Treatment Algorithm

Step 1: Confirm diagnosis of severe allergic conjunctivitis (VKC or atopic) with inadequate response to:

• Topical antihistamines/mast cell stabilizers
• Topical cyclosporine (if tried)
• Topical corticosteroids

Step 2: Select appropriate tacrolimus concentration:

• Age 2-15 years → 0.03% only
• Age ≥16 years with moderate disease → 0.03%
• Age ≥16 years with severe disease → 0.1%

Step 3: Initiate twice-daily application (eyelid ointment or compounded drops)

Step 4: Follow-up at 1-2 weeks to assess tolerance and early response

Step 5: Continue treatment with monthly monitoring, gradually taper concurrent corticosteroids if possible

Step 6: Transition to maintenance therapy once controlled, with less frequent monitoring